Form 4: EyePoint Pharmaceuticals Director Transfers Stock Options to Family Trust

Director Nancy Lurker transferred vested stock options to an irrevocable family trust on July 26, 2024.

Summary

• On July 26, 2024, Nancy Lurker, a director of EyePoint Pharmaceuticals, Inc., transferred vested portions of her stock options to an irrevocable family trust.
• The trust's beneficiaries are Lurker's immediate family members, and her spouse serves as the trustee.
• The transferred options include those exercisable at prices of $12.90, $13.13, $10.13, $3.26, and $9.11.
• The options vest over a four-year period, with 25% vesting at the one-year anniversary of the grant date and the remainder vesting ratably over the subsequent thirty-six months.
• The transfer included options that had already vested in full.
• Lurker disclaims beneficial ownership of the securities held by the Family Trust.

Sentiment

Score: 5

Explanation: The document is a neutral disclosure of stock option transfers, with no inherent positive or negative sentiment.

Industry Context

This filing is a routine disclosure of insider transactions and doesn't necessarily indicate a broader trend within the pharmaceutical industry.

Related Party Transactions

• The transfer of stock options to the family trust constitutes a related party transaction.

Stakeholder Impact

• The transfer of stock options has minimal direct impact on stakeholders, as it is a transfer of ownership rather than a sale or purchase on the open market.

Key Dates